ArticleJournal of intensive care2026
Role and prognostic value of N6-methyladenosine RNA modification regulators in glycolytic reprogramming during sepsis.
Article in Journal of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Matters arising: cellular composition, regulatory directionality, and prognostic reproducibility in m6A-associated glycolytic reprogramming during sepsis.Journal of intensive care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis study aims to investigate the expression profiling characteristics of N6-methyladenosine (m6A) RNA modification regulators in sepsis, their associations with glycolytic metabolic reprogramming, and their preliminary prognostic value.
methodsWe integrated multiple sepsis transcriptomic cohorts (GSE65682, GSE95233, GSE54514) from the GEO database to systematically analyze the differential expression of 15 m6A regulators. Gene Set Variation Analysis (GSVA) scores, weighted gene co-expression network analysis (WGCNA) networks, and Spearman correlation analyses were utilized to assess the associations between m6A regulators and glycolytic activity. The regulation of glycolytic genes by m6A modifications was confirmed using ALKBH5 knockout models (GSE198316, GSE224650) and MeRIP-seq data (GSE225143). A prognostic model was developed by integrating CIBERSORT immune cell infiltration analysis, single-cell RNA sequencing data (GSE147363), and LASSO-Cox regression.
resultsMost m6A regulators are significantly downregulated in patients with sepsis, while IGF2BP2 and IGF2BP3 are upregulated. ALKBH5 clusters with IGF2BP2 within the same WGCNA module and exhibits a positive correlation with glycolytic activity (rho=0.592, P=1.0 × 10⁻
conclusionThese integrated analyses suggest that ALKBH5-associated m6A modification is correlated with sepsis-associated glycolytic reprogramming and support a biologically plausible, hypothesis-generating ALKBH5-associated glycolytic program that requires prospective and experimental validation. The m6A-based four-gene model showed preliminary prognostic potential for 28-day mortality, but its external reproducibility was incomplete and requires validation in larger, prospectively collected and clinically harmonized cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.